Related Experiment Video

Updated: Aug 18, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer

John T Lee1, Linda S Steelman, James A McCubrey

  • 1Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA.

International Journal of Oncology
|May 5, 2005
PubMed

Insights

The Raf/MEK/ERK pathway does not influence prostate cancer chemoresistance. This study found that activating or inhibiting this signaling cascade did not alter the response of prostate cancer cells to chemotherapy drugs like doxorubicin and paclitaxel.

Area of Science:

  • Cellular signaling pathways
  • Cancer biology
  • Drug resistance mechanisms

Background:

  • The Raf/MEK/ERK cascade (MAPK pathway) has complex roles in cell growth and differentiation.
  • Conflicting evidence exists on its role in chemotherapeutic drug resistance, with some studies suggesting pro-survival and others pro-death functions.

Purpose of the Study:

  • To investigate the role of MAPK signaling in the development of drug resistance in advanced prostate cancer.
  • To determine if constitutive activation or inhibition of the Raf/MEK/ERK pathway affects chemoresistance in prostate cancer cells.

Main Methods:

  • Stable transfection of DU145 and PC3 prostate cancer cells with activated Raf-1 and B-Raf mutants.
  • MTT assays to assess cell viability and chemoresistance.
  • Activation of the MAPK pathway with EGF and assessment of response to doxorubicin/paclitaxel with/without MEK inhibitor U0126.

Main Results:

  • Constitutive activation of either Raf-1 or B-Raf did not impact prostate cancer chemoresistance.
  • Inhibition of the MAPK pathway using U0126 did not alter the chemoresistance profile of advanced prostate cancer cells.
  • The response of prostate cancer cells to doxorubicin and paclitaxel was independent of Raf/MEK/ERK signaling.

Conclusions:

  • The Raf/MEK/ERK signaling pathway is not a significant factor in the chemoresistance of advanced prostate cancer.
  • Prostate cancer response to doxorubicin and paclitaxel is independent of MAPK pathway activity.
  • Targeting the MAPK pathway may not be an effective strategy for overcoming chemoresistance in prostate cancer.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...